International Journal of Hematology

DOI: 10.1007/s12185-013-1333-9 Pages: 573-580

Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia

1. King’s College Hospital/King’s College London, Department of Haematological Medicine

Correspondence to:
J. C. W. Marsh
Tel: +44-203-2994153



Alemtuzumab, a humanized anti-CD52, IgG1 monoclonal antibody, is used to reduce graft-versus- host disease (GVHD) and aid engraftment after allogeneic haemopoietic stem cell transplant (HSCT). Its associated low incidence of GVHD makes it an attractive alternative to anti-thymocyte globulin (ATG) in transplant conditioning regimen for severe aplastic anaemia (SAA). We have reviewed the use of alemtuzumab-based conditioning regimen for HSCT in SAA and show that it results in sustained haematological engraftment, a very low incidence of chronic GVHD without an increase in viral infections. Intriguingly, alemtuzumab appears to induce tolerance post-HSCT with the findings of stable mixed T cell chimerism with full donor myeloid chimerism and the absence of chronic GVHD, and which persist on withdrawal of post-graft immunosuppression. Finally, its low toxicity profile may permit future application of HSCT to older patients with SAA who fail to respond to immunosuppressive therapy.

This article is freely available, click here to access the full text/PDF

Share the Knowledge